Supply-Side Drug Policy in the Presence of Substitutes: Evidence from the Introduction of Abuse-Deterrent Opioids

Overdose deaths from prescription opioid pain relievers nearly quadrupled between 1999 and 2010, making this the worst drug overdose epidemic in U.S. history. In response, numerous supply-side interventions have aimed to limit access to opioids. However, these supply disruptions may have the unintended consequence of increasing the use of substitute drugs, including heroin. We study the consequences of one of the largest supply disruptions to date to abusable opioids – the introduction of an abuse-deterrent version of OxyContin in 2010. Our analysis exploits across state variation in exposure to the OxyContin reformulation. Using data from the National Survey on Drug Use and Health (NSDUH), we show that states with higher pre-2010 rates of OxyContin misuse experienced larger reductions in OxyContin misuse, permitting us to isolate consumer substitution responses. We estimate large differential increases in heroin deaths immediately after reformulation in states with the highest initial rates of OxyContin misuse. We find less evidence of differential reductions in overall opioid-related deaths, potentially due to substitution towards other opioids, including more harmful synthetic opioids such as fentanyl. Our results imply that a substantial share of the dramatic increase in heroin deaths since 2010 can be attributed to the reformulation of OxyContin.

[1]  Peter Reuter,et al.  Risks and Prices: An Economic Analysis of Drug Enforcement , 1986, Crime and Justice.

[2]  H. McQuay Opioids in pain management , 1999, The Lancet.

[3]  Feijun Luo,et al.  The Economic Burden of Prescription Opioid Overdose, Abuse, and Dependence in the United States, 2013 , 2016, Medical care.

[4]  H. Wechsler,et al.  Alcohol and Marijuana Use Among College Students: Economic Complements or Substitutes? , 2001, Health economics.

[5]  Robert B. Bolash Trends in opioid analgesic abuse and mortality in the United States. , 2015 .

[6]  N. Nicosia,et al.  Are supply-side drug control efforts effective? Evaluating OTC regulations targeting methamphetamine precursors , 2014 .

[7]  J. V. van Amsterdam,et al.  The Misuse of Prescription Opioids: A Threat for Europe? , 2015, Current drug abuse reviews.

[8]  A. Muñoz,et al.  Trends in abuse of Oxycontin and other opioid analgesics in the United States: 2002-2004. , 2005, The journal of pain : official journal of the American Pain Society.

[9]  J. Davis,et al.  Reduced abuse, therapeutic errors, and diversion following reformulation of extended-release oxycodone in 2010. , 2013, The journal of pain : official journal of the American Pain Society.

[10]  J. Dinardo,et al.  Alcohol, marijuana, and American youth: the unintended consequences of government regulation. , 2001, Journal of health economics.

[11]  P. Reuter,et al.  Does tougher enforcement make drugs more expensive? , 2014, Addiction.

[12]  Sandra E. Ward,et al.  Quality Improvement Guidelines for the Treatment of Acute Pain and Cancer Pain , 1995 .

[13]  J. Zibbell,et al.  Increases in Drug and Opioid Overdose Deaths—United States, 2000–2014 , 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[14]  Sallie-Anne Pearson,et al.  Twenty-five years of prescription opioid use in Australia: a whole-of-population analysis using pharmaceutical claims. , 2016, British journal of clinical pharmacology.

[15]  Scott Cunningham,et al.  Identifying Demand Responses to Illegal Drug Supply Interdictions. , 2016, Health economics.

[16]  Hrishikesh Kale,et al.  Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics , 2013, Pharmacoepidemiology and drug safety.

[17]  Peter Kreiner,et al.  The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction. , 2015, Annual review of public health.

[18]  Jeffrey M. Woodbridge Econometric Analysis of Cross Section and Panel Data , 2002 .

[19]  K. Foley,et al.  Cancer Pain Relief , 1995, Springer Netherlands.

[20]  K. Model,et al.  The Effect of Marijuana Decriminalization on Hospital Emergency Room Drug Episodes: 1975–1978 , 1993 .

[21]  Michael Wooldridge,et al.  Econometric Analysis of Cross Section and Panel Data, 2nd Edition , 2001 .

[22]  J. Caulkins,et al.  What America's Users Spend on Illegal Drugs, 2006–2016 , 2019 .

[23]  H. Chilcoat,et al.  Reductions in reported deaths following the introduction of extended-release oxycodone (OxyContin) with an abuse-deterrent formulation† , 2014, Pharmacoepidemiology and drug safety.

[24]  T. Dmitrieva Report of the International Narcotics Control Board for 2010 , 2010 .

[25]  R. Dart,et al.  Trends in opioid analgesic abuse and mortality in the United States. , 2015, The New England journal of medicine.

[26]  D. Ross-Degnan,et al.  Rates of opioid dispensing and overdose after introduction of abuse-deterrent extended-release oxycodone and withdrawal of propoxyphene. , 2015, JAMA internal medicine.

[27]  T. Buchmueller,et al.  The Effect of Prescription Drug Monitoring Programs on Opioid Utilization in Medicare , 2016 .

[28]  H. Surratt,et al.  Factors influencing the selection of hydrocodone and oxycodone as primary opioids in substance abusers seeking treatment in the United States , 2013, PAIN®.

[29]  Leonard J. Paulozzi,et al.  Vital Signs: Variation Among States in Prescribing of Opioid Pain Relievers and Benzodiazepines — United States, 2012 , 2014, MMWR. Morbidity and mortality weekly report.

[30]  L. Paulozzi Prescription drug overdoses: a review. , 2012, Journal of safety research.

[31]  Li-Hui Chen,et al.  Trends in drug-poisoning deaths involving opioid analgesics and heroin : United States, 1999–2012 , 2014 .

[32]  R. Pacula,et al.  Do Medical Marijuana Laws Reduce Addictions and Deaths Related to Pain Killers? , 2015, Journal of health economics.

[33]  Jonathan P. Caulkins,et al.  How Drug Enforcement Affects Drug Prices , 2010, Crime and Justice.

[34]  Minxing Chen,et al.  Reductions in prescription opioid diversion following recent legislative interventions in Florida , 2014, Pharmacoepidemiology and drug safety.

[35]  P. DasMahapatra,et al.  Changes in prevalence of prescription opioid abuse after introduction of an abuse-deterrent opioid formulation. , 2014, Pain medicine.

[36]  Silvana Tenreyro,et al.  The Log of Gravity , 2004, The Review of Economics and Statistics.

[37]  T. Cicero,et al.  Abuse-Deterrent Formulations and the Prescription Opioid Abuse Epidemic in the United States: Lessons Learned From OxyContin. , 2015, JAMA psychiatry.

[38]  Henry Saffer,et al.  The Demand for Illicit Drugs , 1995 .

[39]  L. Paulozzi,et al.  Decline in Drug Overdose Deaths After State Policy Changes — Florida, 2010–2012 , 2014, MMWR. Morbidity and mortality weekly report.

[40]  Jeffrey M. Wooldridge,et al.  What Are We Weighting For? , 2013, The Journal of Human Resources.

[41]  S. Butler,et al.  Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment. , 2013, The journal of pain : official journal of the American Pain Society.

[42]  N. Nicosia,et al.  The War on Drugs: Methamphetamine, Public Health, and Crime. , 2009, The American economic review.

[43]  H. Surratt,et al.  Effect of abuse-deterrent formulation of OxyContin. , 2012, The New England journal of medicine.

[44]  Benjamin Crost,et al.  The effect of alcohol availability on marijuana use: evidence from the minimum legal drinking age. , 2012, Journal of health economics.

[45]  D. M. Phillips JCAHO Pain Management Standards Are Unveiled , 2000 .

[46]  R. Pacula Does increasing the beer tax reduce marijuana consumption? , 1998, Journal of health economics.